Taysha Gene Therapies, Inc.
Key Metrics
- Previous Close
- $3.99
- 52-Week Range
- $3.46 – $7.30
- Market Cap
- $1.23B
- P/E (TTM)
- —
- EPS (TTM)
- -0.42
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.44
- PEG Ratio
- —
- Return on Equity
- -54.18%
- Return on Assets
- -27.35%
- Gross Margin
- 100.00%
- Operating Margin
- -2998.00%
- Profit Margin
- 0.00%
- Current Ratio
- 18.56
- Debt/Equity
- 0.15
- Total Debt
- $54.59M
- Free Cash Flow
- $-90.18M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $860.95M
Market Snapshot
About
Taysha Gene Therapies is a clinical-stage gene therapy company focused on developing treatments for monogenic diseases of the central nervous system. The company utilizes adeno-associated virus-based gene therapies designed to deliver functional genes to address genetic mutations. Taysha is advancing a pipeline of investigational therapies for rare neurological disorders.